Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy

被引:54
作者
Repajic, Michael [1 ]
Lai, Xue Lei [1 ]
Xu, Prissilla [2 ]
Liu, Antonio [1 ]
机构
[1] Adventist Hlth White Mem, Dept Neurol, Los Angeles, CA 90033 USA
[2] Adventist Hlth White Mem, Dept Pharm Serv, Los Angeles, CA USA
关键词
D O I
10.1016/j.bbih.2021.100217
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To report a patient with history of recurrent Bell's Palsy who developed Bell's Palsy 36 h after the administration of the second dose of the Pfizer-BioNTech COVID-19 vaccine. Case: The patient is a 57-year-old female with past medical history of 3 episodes of Bell's Palsy. She responded to prednisone treatment and returned to her baseline after each occurrence. Less than 36 h following the second dose of the vaccine, the patient developed a left Bell's Palsy. The facial droop progressed in severity over the next 72 h. Conclusion: Given the expedited production of the vaccine and the novelty associated with its production, there may be information pertaining to side effects and individual response that remain to be discovered. Since both the Moderna and Pfizer Vaccine trials reported Bell's Palsy as medically attended adverse events, the association between vaccine administration and onset of symptomatic Bell's Palsy may warrant further investigation.
引用
收藏
页数:2
相关论文
共 8 条
  • [1] [Anonymous], 2020, Pfizer-BioNTech COVID-19 vaccine
  • [2] [Anonymous], 2020, MOD COVID 19 VACC RE
  • [3] Recurrent Bell's palsy
    Dong, Sung Hwa
    Jung, Ah Ra
    Jung, Junyang
    Jung, Su Young
    Byun, Jae Yong
    Park, Moon Suh
    Kim, Sang Hoon
    Yeo, Seung Geun
    [J]. CLINICAL OTOLARYNGOLOGY, 2019, 44 (03) : 305 - 312
  • [4] Rapid COVID-19 vaccine development
    Graham, Barney S.
    [J]. SCIENCE, 2020, 368 (6494) : 945 - 946
  • [5] Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595
  • [6] Spencer JP, 2017, AM FAM PHYSICIAN, V95, P786
  • [7] The Center for Disease Control and Prevention, 2021, Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States, V6
  • [8] A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001
    Zhou, WG
    Pool, V
    DeStefano, F
    Iskander, JK
    Haber, P
    Chen, RT
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2004, 13 (08) : 505 - 510